Population pharmacokinetics and exposure–response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma
Dosne A, Li X, Luo M, Nnane I, Dimopoulos M, Terpos E, Sonneveld P, Kampfenkel T, Carson R, Amin H, Ruixo J, Zhou H, Sun Y, Xu Y. Population pharmacokinetics and exposure–response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma. British Journal Of Clinical Pharmacology 2022, 89: 1640-1655. PMID: 36484341, DOI: 10.1111/bcp.15628.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsExposure-response analysesPPK analysisPPK modelTwo-compartment PPK modelExposure to daratumumabProgression-free survivalNo dose adjustmentRefractory multiple myelomaExposure-responseTreatment of patientsClinically relevant effectsConcentration-time dataDaratumumab administrationDaratumumab exposureDaratumumab monotherapyDose adjustmentDosing regimenCharacterize pharmacokineticsMultiple myelomaPK samplingDaratumumabAdverse eventsPopulation pharmacokineticsPK exposure
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply